Srijita Chakrabarti

Ms. Srijita Chakrabarti


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2019 in Toxicology and Industrial Health
Verified
Journal Article
Closed access
PDF file
SCSrijita Chakrabarti
Srijita Chakrabarti
DGDanswrang Goyary
Danswrang Goyary
SKSanjeev Karmakar
Sanjeev Karmakar
PCPronobesh Chattopadhyay
Pronobesh Chattopadhyay
Health hazards of titanium dioxide nanoparticles (TiO2-NPs) have raised severe concerns because of the paucity of information regarding the toxic effects among the population. In the present research, the in vitro and in vivo cytotoxic potential of TiO2-NPs were evaluated using flow cytometric techniques. Further, in vitro and in vivo genotoxic endpoints were estimated by means of comet, micronucleus (MN), and chromosomal aberration (CA) assays. In vitro analysis was performed at the concentration range of 10–100 µg/mL using murine RAW 264.7 cells. In vivo experiments were conducted on Albino mice (M/F) by exposing them to 200 and 500 mg/kg TiO2-NPs for 90 days. Decreased percentage of cell viability with higher doses of TiO2-NPs was evident in both in vitro and in vivo flow cytometric analysis. Further, an impaired cell cycle (G0/G1, S, and G2/M) was reflected in the present investigation following the exposure to TiO2-NPs. Increased comet scores such as tail length, % DNA in tail, tail moment, and olive moment were also observed with the higher doses of TiO2-NPs in vitro and in vivo comet assays. Finally, the in vivo MN and CA assays revealed the formation of MN and chromosomal breakage following the exposure to TiO2-NPs.

2 February 2026 in Journal of Essential Oil Research
Verified
Journal Article
Closed access
AAAmeena Ahmed
Ameena Ahmed
PBPervej Alom Barbhuiya
Pervej Alom Barbhuiya
PKPunam Kumari
Punam Kumari
SCSrijita Chakrabarti
Srijita Chakrabarti
MPManash Pratim Pathak
Manash Pratim Pathak

23 April 2026 in Biochemical and Biophysical Research Communications
Verified
Journal Article
Closed access
SCSrijita Chakrabarti
Srijita Chakrabarti
RARejaul Karim Ahmed
Rejaul Karim Ahmed
SNShibanth Nath
Shibanth Nath
ANAnmoy Nandi
Anmoy Nandi
MPManash Pratim Pathak
Manash Pratim Pathak

1 November 2024 in Current Nanomedicine
Verified
Journal Article
Closed access
PDF file
ADArnab Das
Arnab Das
SCSrijita Chakrabarti
Srijita Chakrabarti
: The fields of nanotechnology and nanomedicine have undergone a revolution. There has been a striking rise in authorized nanomedicines since 1980. Apart from functioning as thera-peutic agents, they also act as carriers for delivering various active pharmaceuticals to target or-gans. The ultimate goal of nanomedicine has always been the generation of translational technol-ogies that can improve current therapies. Nanocrystals, nanotubes, liposomes, exosomes, solid li-pid nanoparticles, polymeric nanoparticles, and metallic and magnetic nanoparticles are examples of nanostructures that are now in the market as well as in ongoing research. The preparation of these nanomaterials requires consideration of a number of difficulties. Only a few of these nano-materials were successful in obtaining marketing permission after passing all required toxicologi-cal and ethical evaluations and making them affordable to users and, at the same time, profitable to investors. Cancer, central nervous system (CNS) diseases, and cardiovascular (CVS) diseases represented the primary targets of nanotechnology applied to medicine. Therefore, this review ar-ticle is focused on providing a summary of several nano-based delivery systems, including their limitations and prospects in different therapeutic fields.


2 July 2026 in Recent Advances in Drug Delivery and Formulation
Verified
Journal Article
Closed access
PDF file
ANAnmoy Nandi
Anmoy Nandi
DCDevid Chutia
Devid Chutia
DDDebasmita Das
Debasmita Das
SCSrijita Chakrabarti
Srijita Chakrabarti
Microemulsion-based drug delivery systems are increasingly attracting attention in the pharmaceutical field owing to their remarkable capacity to enhance solubility, stability, and bioavailability, as well as enable targeted drug delivery. These systems comprise clear, stable, isotropic blends of oil, water, and surfactant, often accompanied by a co-surfactant. Their appeal to pharmaceutical scientists lies in their versatility as effective drug-delivery vehicles, accommodating a diverse array of drug molecules. Microemulsions have demonstrated effectiveness in protecting fragile drugs, controlling drug release, enhancing solubility, increasing bioavailability, and reducing variation in patient response. Moreover, formulations suitable for various routes of administration have been successfully devised. Since their discovery, microemulsions have gained prominence, becoming increasingly vital in both academic research and industrial settings due to their distinct characteristics, such as reduced interfacial tension, extensive interfacial area, thermodynamic stability, and the ability to solubilize otherwise immiscible substances. Transparent appearance, low viscosity, and inherent thermodynamic stability set microemulsions apart from conventional emulsions. This review aims to elucidate the potential of microemulsions as delivery vehicles and to provide insights into their formation principles. Additionally, it comprehensively explores microemulsion-based drug delivery systems, encompassing oral, topical, transdermal, ocular, and parenteral delivery methods, with a focus on recent advancements, existing challenges, and future trajectories.